On 6 January 2023, the FDA approved Biogen and Eisai's monoclonal antibody, lecanemab, under the accelerated approval process. The drug, to be marketed as Leqembi in the US, is indicated for the treatment of Alzheimer's disease. While not directly impacting IXICO, we believe this approval will add further momentum to the Alzheimer's disease clinical development market, which should benefit IXICO's growth in this therapy area in the mid- to long-term. IXICO is well established in the Alzheimer's ....
09 Jan 2023
Cenkos: IXICO Plc -- Leqembi approval
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: IXICO Plc -- Leqembi approval
IXICO Plc (IXI:LON) | 8.8 0 0.0% | Mkt Cap: 4.23m
- Published:
09 Jan 2023 -
Author:
Chris Donnellan -
Pages:
7
On 6 January 2023, the FDA approved Biogen and Eisai's monoclonal antibody, lecanemab, under the accelerated approval process. The drug, to be marketed as Leqembi in the US, is indicated for the treatment of Alzheimer's disease. While not directly impacting IXICO, we believe this approval will add further momentum to the Alzheimer's disease clinical development market, which should benefit IXICO's growth in this therapy area in the mid- to long-term. IXICO is well established in the Alzheimer's ....